TKT and non-small cell lung carcinoma: Three recent studies have demonstrated that gefitinib, another EGFR TK inhibitor, induced dramatic clinical responses in non-small-cell lung cancers with activating mutations within the EGFR kinase domain (Lynch et al, 2004; Paez et al, 2004; Pao et al, 2004).